Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 6;11(12):3231.
doi: 10.3390/biomedicines11123231.

Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients

Cristina Arqueros  1   2 , Juliana Salazar  3 , Alberto Gallardo  4   5   6 , Marta Andrés  1 , Ariadna Tibau  1 , Olga Lidia Bell  3 , Alícia Artigas  7 , Adriana Lasa  7   8 , Teresa Ramón Y Cajal  1 , Enrique Lerma  4   5   6 , Agustí Barnadas  1   9
Affiliations

Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients

Cristina Arqueros et al. Biomedicines. .

Abstract

Secreted protein acidic and rich in cysteine (SPARC) expression has been proposed as a prognostic and predictive biomarker for some cancer types, but knowledge about the predictive value of SPARC polymorphisms in the context of neoadjuvant therapy for breast cancer (BC) is lacking. In 132 HER2-negative BC patients treated with neoadjuvant chemotherapy, we determined polymorphisms in the SPARC gene and analyzed their association with outcome. We also determined SPARC protein expression in tumor tissue. SPARC rs19789707 was significantly associated with response to treatment according to the Miller and Payne system in the breast (multivariate: odds ratio (OR), 3.81; p = 0.028). This association was significant in the subgroup of patients with luminal tumors (univariate: p = 0.047). Regarding survival, two SPARC variants showed significant associations with event-free survival: the rs19789707 variant in the subgroup of luminal A tumors (univariate: p = 0.006), and the rs4958487 variant in the subgroup of luminal B tumors (univariate: p = 0.022). In addition, SPARC rs4958487, rs10065756, and rs12153644 were significantly correlated with SPARC protein expression. Our findings suggest that SPARC polymorphisms could be good predictors of treatment response and survival in BC patients treated with neoadjuvant chemotherapy, especially those with luminal tumors.

Keywords: SPARC; biomarker; breast cancer; neoadjuvant therapy; polymorphisms.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Event-free survival according to (A) SPARC rs19789707 variant in patients with luminal A breast cancer; (B) SPARC rs4958487 variant in patients with luminal B breast cancer.
Figure 1
Figure 1
Event-free survival according to (A) SPARC rs19789707 variant in patients with luminal A breast cancer; (B) SPARC rs4958487 variant in patients with luminal B breast cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bear H.D., Anderson S., Smith R.E., Geyer C.E., Mamounas E.P., Fisher B., Brown A.M., Robidoux A., Margolese R., Kahlenberg M.S., et al. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 2006;24:2019–2027. doi: 10.1200/JCO.2005.04.1665. - DOI - PubMed
    1. Buzdar A.U., Singletary S.E., Theriault R.L., Booser D.J., Valero V., Ibrahim N., Smith T.L., Asmar L., Frye D., Manuel N., et al. Prospective Evaluation of Paclitaxel versus Combination Chemotherapy with Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients with Operable Breast Cancer. J. Clin. Oncol. 1999;17:3412–3417. doi: 10.1200/JCO.1999.17.11.3412. - DOI - PubMed
    1. Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., Symmans W.F., Gonzalez-Angulo A.M., Hennessy B., Green M., et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer. J. Clin. Oncol. 2008;26:1275–1281. doi: 10.1200/JCO.2007.14.4147. - DOI - PubMed
    1. Untch M., Fasching P.A., Konecny G.E., Hasmüller S., Lebeau A., Kreienberg R., Camara O., Müller V., Du Bois A., Kuḧn T., et al. Pathologic Complete Response after Neoadjuvant Chemotherapy plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results from the TECHNO Trial of the AGO and GBG Study Groups. J. Clin. Oncol. 2011;29:3351–3357. doi: 10.1200/JCO.2010.31.4930. - DOI - PubMed
    1. Von Minckwitz G., Untch M., Blohmer J.U., Costa S.D., Eidtmann H., Fasching P.A., Gerber B., Eiermann W., Hilfrich J., Huober J., et al. Definition and Impact of Pathologic Complete Response on Prognosis after Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J. Clin. Oncol. 2012;30:1796–1804. doi: 10.1200/JCO.2011.38.8595. - DOI - PubMed

Grants and funding

This research received no external funding.
-